Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal LEAP
NCT07798583Phase 3Not yet recruiting
- Sponsor
- Indiana University
- Start
- Jan 2028
- Primary completion
- Jan 2030
01
Overview
Phase 3, randomised, open-label trial of dihydroartemisinin + piperaquine in malaria (2 arms), sponsored by Indiana University. Primary endpoint: Change from baseline to 24 months in NeuroScreen Executive Function Composite z-score. Planned start Jan 2028; status: not yet recruiting.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07798583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798583.